$VCNX
Vaccinex Inc

2023 Q4 Form 10-Q Financial Statement

#000095017023062454 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $20.00K
YoY Change -100.0% -60.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.631M $1.500M
YoY Change 1.75% 6.16%
% of Gross Profit
Research & Development $3.357M $4.355M
YoY Change -10.26% 27.0%
% of Gross Profit
Depreciation & Amortization $29.00K $31.00K
YoY Change -35.56% -53.73%
% of Gross Profit
Operating Expenses $4.988M $4.355M
YoY Change -6.66% 27.0%
Operating Profit -$5.834M
YoY Change 21.74%
Interest Expense -$383.0K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $2.054M $922.0K
YoY Change 4909.76% 2611.76%
Pretax Income -$3.317M -$4.912M
YoY Change -34.68% 3.21%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.317M -$4.912M
YoY Change -34.68% 3.21%
Net Earnings / Revenue -24560.0%
Basic Earnings Per Share -$1.09
Diluted Earnings Per Share -$3.29 -$1.09
COMMON SHARES
Basic Shares Outstanding 12.49M 65.94M
Diluted Shares Outstanding 4.507M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.535M $130.0K
YoY Change -75.98% -98.19%
Cash & Equivalents $1.535M $127.0K
Short-Term Investments
Other Short-Term Assets $853.0K $1.150M
YoY Change -6.47% 45.75%
Inventory
Prepaid Expenses
Receivables $961.0K $933.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.349M $2.206M
YoY Change -55.22% -72.51%
LONG-TERM ASSETS
Property, Plant & Equipment $282.0K $164.0K
YoY Change 49.21% -30.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $282.0K $352.0K
YoY Change -43.49% -40.03%
TOTAL ASSETS
Total Short-Term Assets $3.349M $2.206M
Total Long-Term Assets $282.0K $352.0K
Total Assets $3.631M $2.558M
YoY Change -54.48% -70.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.039M $4.225M
YoY Change 34.32% 755.26%
Accrued Expenses $1.388M $1.895M
YoY Change 77.72% 50.88%
Deferred Revenue $63.00K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $75.00K $75.00K
YoY Change 1.35% 1.35%
Total Short-Term Liabilities $5.916M $6.362M
YoY Change 133.19% 220.18%
LONG-TERM LIABILITIES
Long-Term Debt $26.00K $44.00K
YoY Change -74.26% -63.03%
Other Long-Term Liabilities $0.00 $20.00K
YoY Change -100.0% -89.36%
Total Long-Term Liabilities $26.00K $44.00K
YoY Change -74.26% -63.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.916M $6.362M
Total Long-Term Liabilities $26.00K $44.00K
Total Liabilities $5.942M $6.427M
YoY Change 113.43% 180.17%
SHAREHOLDERS EQUITY
Retained Earnings -$339.9M -$336.6M
YoY Change 6.32% 6.99%
Common Stock $337.6M $332.8M
YoY Change 3.92% 3.68%
Preferred Stock
YoY Change
Treasury Stock (at cost) $11.00K $11.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity -$2.311M -$3.870M
YoY Change
Total Liabilities & Shareholders Equity $3.631M $2.558M
YoY Change -54.48% -70.3%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$3.317M -$4.912M
YoY Change -34.68% 3.21%
Depreciation, Depletion And Amortization $29.00K $31.00K
YoY Change -35.56% -53.73%
Cash From Operating Activities -$3.594M -$3.090M
YoY Change -21.85% -25.47%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $20.00K
YoY Change 50.0% -140.82%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $3.000K -$20.00K
YoY Change 50.0% -59.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.995M 1.340M
YoY Change 31.38% -7152.63%
NET CHANGE
Cash From Operating Activities -3.594M -3.090M
Cash From Investing Activities 3.000K -20.00K
Cash From Financing Activities 4.995M 1.340M
Net Change In Cash 1.404M -1.770M
YoY Change -276.6% -58.0%
FREE CASH FLOW
Cash From Operating Activities -$3.594M -$3.090M
Capital Expenditures -$3.000K $20.00K
Free Cash Flow -$3.591M -$3.110M
YoY Change -21.88% -24.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001205922
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38624
dei Entity Registrant Name
EntityRegistrantName
Vaccinex, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
16-1603202
dei Entity Address Address Line1
EntityAddressAddressLine1
1895 Mount Hope Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Rochester
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
14620
dei City Area Code
CityAreaCode
585
dei Local Phone Number
LocalPhoneNumber
271-2700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
VCNX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12494275
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6391000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
933000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
175000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1146000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
912000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
2206000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
7478000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
189000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
188000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
310000
CY2023Q3 us-gaap Assets
Assets
2558000
CY2022Q4 us-gaap Assets
Assets
7977000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4225000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1518000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1895000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
781000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
75000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
74000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
167000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
164000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6362000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2537000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
44000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
101000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146000
CY2023Q3 us-gaap Liabilities
Liabilities
6427000
CY2022Q4 us-gaap Liabilities
Liabilities
2784000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4858530
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3325441
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4858473
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3325384
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
332752000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
324880000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
57
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
57
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
11000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
11000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-336610000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319676000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3869000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5193000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2558000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7977000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
570000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4355000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3429000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13217000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10238000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1499000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1413000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5250000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4599000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
5854000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
4842000
us-gaap Costs And Expenses
CostsAndExpenses
18467000
us-gaap Costs And Expenses
CostsAndExpenses
14837000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5834000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4792000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17897000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14787000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1000
us-gaap Interest Expense
InterestExpense
1000
us-gaap Interest Expense
InterestExpense
2000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
922000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
964000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4912000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4759000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16934000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14737000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4912000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4759000
us-gaap Net Income Loss
NetIncomeLoss
-16934000
us-gaap Net Income Loss
NetIncomeLoss
-14737000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4912000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4759000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16934000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14737000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.34
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4506834
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4506834
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2844270
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2844270
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3953431
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3953431
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2757475
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2757475
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7412000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13230000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
141000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4595000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16188000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-5383000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10943000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
134000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-4759000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6318000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5193000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2040000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
129000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4962000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2400000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4111000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
126000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-7060000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-423000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1351000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1351000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
115000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-4912000
CY2023Q3 us-gaap Shares Outstanding
SharesOutstanding
4858530
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3869000
us-gaap Profit Loss
ProfitLoss
-16934000
us-gaap Profit Loss
ProfitLoss
-14737000
us-gaap Depreciation
Depreciation
92000
us-gaap Depreciation
Depreciation
162000
us-gaap Share Based Compensation
ShareBasedCompensation
370000
us-gaap Share Based Compensation
ShareBasedCompensation
413000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
758000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
50000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-27000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2707000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-567000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
864000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
277000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13642000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14475000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
101000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1268000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3519000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
57000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
56000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6234000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
9710000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7445000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13173000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6264000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1403000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6391000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8589000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
127000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7186000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13600000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-336600000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Company effected a 1-for-15 reverse stock split of its issued shares of common stock (the "Reverse Stock Split"). All per share amounts, common shares outstanding and stock-based compensation amounts for all periods presented have been retroactively adjusted to reflect the Reverse Stock Split.
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.15
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These condensed financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks, including, but not limited to, the lack of available capital; the possible delisting of our common stock from Nasdaq, possible failure of preclinical testing or clinical trials; inability to obtain regulatory approval of product candidates; competitors developing new technological innovations; potential interruptions in the manufacturing and commercial supply operations; unsuccessful commercialization strategy and launch plans for its proprietary drug candidates; risks inherent in litigation, including purported class actions; market acceptance of the Company’s products; and protection of proprietary technology.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically raised capital in transactions with investors that include members of its board of directors and entities controlled by certain board members. As such, the Company's directors, directly and indirectly, control a significant ownership percentage of the Company. The Company can provide no assurances that future financing will be available in sufficient amounts or on terms acceptable to it or that its directors or entities controlled by certain board members will be willing or able to participate in future capital raises by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company depends on third-party manufacturers for the manufacture of drug substances and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Retention Credit</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) provided refundable employee retention credits, which could be used to offset payroll tax liabilities. Under the provisions of the extension of the CARES Act, the Company qualified for the employee retention credit for the last three quarters of 2020, and first three quarters of 2021, and the Company applied for the credit in September 2023. As there is no authoritative guidance under U.S. GAAP for accounting for grants to for-profit business entities, the Company accounted for the grant by applying Accounting Standards Codification (“ASC”) 450, Contingencies. The Company recognized an employee retention credit receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of September 30, 2023 in accounts receivable on the condensed balance sheet. The Company recognized the employee retention credit during the three and nine months ended September 30, 2023 as a component of other income (expense), net on the condensed statement of operations and comprehensive income (loss).</span></p></div>
vcnx Employee Retetion Credit
EmployeeRetetionCredit
900000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7228000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7445000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7064000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7256000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
189000
CY2023Q3 us-gaap Depreciation
Depreciation
31000
us-gaap Depreciation
Depreciation
92500
CY2022Q3 us-gaap Depreciation
Depreciation
67000
us-gaap Depreciation
Depreciation
162000
CY2023Q3 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
1220000
CY2022Q4 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
335000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
287000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
308000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
382000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
127000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1895000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
781000
CY2017Q4 vcnx Number Of Target Antigens Against Which Antibodies Are To Be Identified And Selected
NumberOfTargetAntigensAgainstWhichAntibodiesAreToBeIdentifiedAndSelected
2
CY2022Q4 vcnx Minimum Bid Price Requirement Per Share For Listing
MinimumBidPriceRequirementPerShareForListing
1
vcnx Stock Exchange Stock Trading Price Description
StockExchangeStockTradingPriceDescription
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company received a second 180-day compliance period, or until October 9, 2023, to regain compliance with the minimum bid price requirement. The Company did not regain compliance by October 9, 2023 and received a notice from Nasdaq that its stock is subject to delisting. The Company appealed the delisting notice and has received an extension until March 4, 2024 to regain compliance with the minimum bid price requirement, subject to fulfilling its commitments to regain compliance by such date. There can be no assurance that the Company will be able to regain compliance with the Nasdaq minimum bid price requirements or that its common stock will continue to be listed on Nasdaq.
CY2022Q4 vcnx Minimum Bid Price Requirement Threshold Consecutive Business Days To Regain Compliance
MinimumBidPriceRequirementThresholdConsecutiveBusinessDaysToRegainCompliance
P180D
CY2023Q2 vcnx Minimum Stockholders Equity Required For Listing
MinimumStockholdersEquityRequiredForListing
2500000
CY2023Q2 vcnx Market Value Of Listed Securities
MarketValueOfListedSecurities
35000000
CY2023Q2 vcnx Net Income From Continuing Operations Related To Listing
NetIncomeFromContinuingOperationsRelatedToListing
500000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2400000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3900000
us-gaap Lessee Operating Lease Assumptions And Judgments Discount Rate Description
LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription
The leases do not provide an implicit rate so in determining the present value of lease payments, the Company its incremental borrowing rate for the applicable lease, which was 7.0%.
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
195626
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7760
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
187866
us-gaap Operating Lease Payments
OperatingLeasePayments
135434
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
45144
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
44000
us-gaap Operating Lease Expense
OperatingLeaseExpense
135433
us-gaap Operating Lease Expense
OperatingLeaseExpense
131000
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
210812
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
144316
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
118795
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
59.68
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
91689
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
211
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
90.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4386
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
223.6
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
205887
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
95956
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
56.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
513718
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
604626
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
572490
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
561198
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
115000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
134000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
370000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
413000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
vcnx Number Of Business Activity
NumberOfBusinessActivity
1
vcnx Number Of Segment Managers For Operations Or Operating Results
NumberOfSegmentManagersForOperationsOrOperatingResults
0
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
45144
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
44000
us-gaap Operating Lease Expense
OperatingLeaseExpense
135433
us-gaap Operating Lease Expense
OperatingLeaseExpense
131000

Files In Submission

Name View Source Status
0000950170-23-062454-index-headers.html Edgar Link pending
0000950170-23-062454-index.html Edgar Link pending
0000950170-23-062454.txt Edgar Link pending
0000950170-23-062454-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vcnx-20230930.htm Edgar Link pending
vcnx-20230930.xsd Edgar Link pending
vcnx-ex31_1.htm Edgar Link pending
vcnx-ex31_2.htm Edgar Link pending
vcnx-ex32_1.htm Edgar Link pending
vcnx-20230930_cal.xml Edgar Link unprocessable
vcnx-20230930_def.xml Edgar Link unprocessable
vcnx-20230930_lab.xml Edgar Link unprocessable
vcnx-20230930_pre.xml Edgar Link unprocessable
vcnx-20230930_htm.xml Edgar Link completed